University of Hertfordshire

Integrating PRO Assessment in Clinical Trials, Routine Clinical Practice and Medicines Development Programmes

Research output: Chapter in Book/Report/Conference proceedingChapter

Standard

Integrating PRO Assessment in Clinical Trials, Routine Clinical Practice and Medicines Development Programmes. / Kamudoni, Paul; Johns, Nutjaree; Salek, Mir-Saeed Shayegan.

Living with Chronic Disease: Measuring Important Patient-Reported Outcomes. Singapore : Adis, 2018. p. 143-165.

Research output: Chapter in Book/Report/Conference proceedingChapter

Harvard

Kamudoni, P, Johns, N & Salek, M-SS 2018, Integrating PRO Assessment in Clinical Trials, Routine Clinical Practice and Medicines Development Programmes. in Living with Chronic Disease: Measuring Important Patient-Reported Outcomes. Adis, Singapore, pp. 143-165. https://doi.org/10.1007/978-981-10-8414-0_7

APA

Kamudoni, P., Johns, N., & Salek, M-S. S. (2018). Integrating PRO Assessment in Clinical Trials, Routine Clinical Practice and Medicines Development Programmes. In Living with Chronic Disease: Measuring Important Patient-Reported Outcomes (pp. 143-165). Adis. https://doi.org/10.1007/978-981-10-8414-0_7

Vancouver

Kamudoni P, Johns N, Salek M-SS. Integrating PRO Assessment in Clinical Trials, Routine Clinical Practice and Medicines Development Programmes. In Living with Chronic Disease: Measuring Important Patient-Reported Outcomes. Singapore: Adis. 2018. p. 143-165 https://doi.org/10.1007/978-981-10-8414-0_7

Author

Kamudoni, Paul ; Johns, Nutjaree ; Salek, Mir-Saeed Shayegan. / Integrating PRO Assessment in Clinical Trials, Routine Clinical Practice and Medicines Development Programmes. Living with Chronic Disease: Measuring Important Patient-Reported Outcomes. Singapore : Adis, 2018. pp. 143-165

Bibtex

@inbook{8b8587c3464f4f3385284d604e96ad09,
title = "Integrating PRO Assessment in Clinical Trials, Routine Clinical Practice and Medicines Development Programmes",
abstract = "It is futile to have the most optimised PRO measure developed if it is going to gather dust on the shelf without any use. Whether a PRO measure can be easily integrated into clinical research or clinical practice may depend on several issues—specific to the PRO measure, factors related to the context of use and the potential users. This chapter is intended to discuss the process, key considerations and pitfalls in the application of PRO measures across the different settings – clinical trials, routine clinical practice, medicines regulatory and HTA processes. This represents Step VIII, the final step, of the roadmap presented in this book. We have included findings from some of our research, first, to illustrate integration of PROs in palliative care and chronic pain clinics, and second, perspectives of industry executives and regulators on PROs. We conclude the chapter, with some recommendations on enhancing the application of PRO assessments across different settings.",
author = "Paul Kamudoni and Nutjaree Johns and Salek, {Mir-Saeed Shayegan}",
year = "2018",
month = sep,
day = "7",
doi = "10.1007/978-981-10-8414-0_7",
language = "English",
isbn = "978-981-10-8413-3",
pages = "143--165",
booktitle = "Living with Chronic Disease: Measuring Important Patient-Reported Outcomes",
publisher = "Adis",

}

RIS

TY - CHAP

T1 - Integrating PRO Assessment in Clinical Trials, Routine Clinical Practice and Medicines Development Programmes

AU - Kamudoni, Paul

AU - Johns, Nutjaree

AU - Salek, Mir-Saeed Shayegan

PY - 2018/9/7

Y1 - 2018/9/7

N2 - It is futile to have the most optimised PRO measure developed if it is going to gather dust on the shelf without any use. Whether a PRO measure can be easily integrated into clinical research or clinical practice may depend on several issues—specific to the PRO measure, factors related to the context of use and the potential users. This chapter is intended to discuss the process, key considerations and pitfalls in the application of PRO measures across the different settings – clinical trials, routine clinical practice, medicines regulatory and HTA processes. This represents Step VIII, the final step, of the roadmap presented in this book. We have included findings from some of our research, first, to illustrate integration of PROs in palliative care and chronic pain clinics, and second, perspectives of industry executives and regulators on PROs. We conclude the chapter, with some recommendations on enhancing the application of PRO assessments across different settings.

AB - It is futile to have the most optimised PRO measure developed if it is going to gather dust on the shelf without any use. Whether a PRO measure can be easily integrated into clinical research or clinical practice may depend on several issues—specific to the PRO measure, factors related to the context of use and the potential users. This chapter is intended to discuss the process, key considerations and pitfalls in the application of PRO measures across the different settings – clinical trials, routine clinical practice, medicines regulatory and HTA processes. This represents Step VIII, the final step, of the roadmap presented in this book. We have included findings from some of our research, first, to illustrate integration of PROs in palliative care and chronic pain clinics, and second, perspectives of industry executives and regulators on PROs. We conclude the chapter, with some recommendations on enhancing the application of PRO assessments across different settings.

U2 - 10.1007/978-981-10-8414-0_7

DO - 10.1007/978-981-10-8414-0_7

M3 - Chapter

SN - 978-981-10-8413-3

SP - 143

EP - 165

BT - Living with Chronic Disease: Measuring Important Patient-Reported Outcomes

PB - Adis

CY - Singapore

ER -